AUS
NZ
UK
CA
USA
IND
On July 28, 2026, Altimmune, Inc. revealed encouraging topline outcomes from its RECLAIM Phase 2 study assessing the 2.4 mg dose of pemvidutide in patients with moderate to severe alcohol use disorder (AUD). This investigational glucagon/GLP-1 dual receptor agonist successfully achieved its primary endpoint and showed favorable results across secondary endpoints, alongside a positive safety profile. Following these findings, the company intends to seek an End-of-Phase 2 meeting with the FDA to discuss next steps.
Key Points
- Trading on NASDAQ under ticker: ALT
- Pemvidutide 2.4 mg demonstrated a statistically significant reduction in heavy drinking days per week compared to placebo, meeting the primary endpoint
- Trial achieved positive outcomes on FDA registrational endpoints, including a two-level decrease in World Health Organization Risk Drinking Level and elimination of heavy drinking days
- Altimmune plans to pursue an End-of-Phase 2 FDA meeting following trial success
RECLAIM Phase 2 Trial Meets Primary Efficacy Endpoint
Altimmune announced that the RECLAIM Phase 2 trial achieved its primary endpoint, showing a highly statistically significant reduction in heavy drinking days per week for patients receiving the 2.4 mg dose of pemvidutide versus placebo. This result represents a meaningful clinical advance in the AUD treatment landscape, where therapeutic options remain limited. The reduction in heavy drinking days is a key efficacy measure for AUD therapies and a critical regulatory benchmark.
The statistically significant primary endpoint supports pemvidutide as a potentially differentiated treatment approach. The 2.4 mg dose was selected based on prior clinical data and safety considerations, demonstrating an optimal balance between efficacy and tolerability in the study population, which may be pivotal for future development and commercialization.
Positive Secondary Endpoints and FDA Registrational Measures
In addition to the primary endpoint, the RECLAIM trial showed positive results on important secondary endpoints, including a two-level reduction in the World Health Organization Risk Drinking Level and achieving zero heavy drinking days. Both endpoints are recognized as FDA registrational markers, aligning with regulatory expectations for pivotal trial design and potentially facilitating discussions on the development pathway for pemvidutide in AUD.
The study also reported reductions in phosphatidyl ethanol levels, a biomarker for alcohol consumption and abstinence, providing multiple lines of evidence supporting the drug’s mechanism of action. These combined behavioral and biomarker improvements strengthen the clinical profile presented to investors and regulators.
Favorable Safety and Tolerability Profile
Altimmune reported a generally favorable safety and tolerability profile for pemvidutide throughout the RECLAIM trial. While specific adverse event details, rates, or discontinuation data were not disclosed, the company’s characterization suggests the 2.4 mg dose was well tolerated in the AUD patient population. Comprehensive safety data are expected in more detailed clinical reports.
Safety and tolerability are particularly important in AUD treatment due to patient health complexities and adherence challenges. A positive safety profile may support patient compliance and clinical utility if pemvidutide advances to later-stage development and commercialization. No specific safety comparisons versus placebo or emerging safety signals were mentioned in this announcement.
Mechanism of Action: Dual Glucagon/GLP-1 Receptor Agonist
Pemvidutide is described as an investigational balanced glucagon/GLP-1 dual receptor agonist, a novel mechanism for AUD treatment. This dual action may influence neural reward pathways, appetite regulation, and metabolic functions potentially linked to alcohol use behaviors and cravings, although detailed biological rationale was not provided.
This dual receptor approach differs from currently approved AUD medications, which primarily target opioid or GABA systems. If successful, pemvidutide could offer an alternative for patients unresponsive or intolerant to existing therapies. The novel mechanism may also enhance intellectual property protection and commercial differentiation in the AUD market.
Plans for End-of-Phase 2 FDA Meeting
Altimmune intends to request an End-of-Phase 2 meeting with the FDA based on the RECLAIM results. This regulatory milestone allows the company to engage with FDA reviewers to discuss the clinical development plan and obtain feedback on the pathway toward pivotal trials. Details on the timing or specific agenda for this meeting were not disclosed.
Pursuing this meeting reflects management’s confidence in the data and intent to advance pemvidutide into Phase 3 development. Discussions typically cover trial design, endpoint selection, patient populations, and regulatory expectations, which will influence future clinical trial strategies and approval pathways.
Clinical Development Timeline and Regulatory Outlook
The announcement does not specify timelines for the End-of-Phase 2 meeting or subsequent clinical activities. Investors will look for updates on regulatory interactions and plans for Phase 3 evaluation. The FDA’s feedback from this meeting will be critical in determining whether one or multiple pivotal trials are required for New Drug Application submission, shaping Altimmune’s development strategy and resource allocation.
The positive Phase 2 data position pemvidutide well for continued clinical advancement, contingent on supportive regulatory guidance.
Alcohol Use Disorder Market Landscape
Alcohol use disorder affects millions in the U.S. and worldwide, representing a significant public health challenge. Current FDA-approved treatments include naltrexone, acamprosate, and disulfiram, each with distinct mechanisms and variable patient acceptance. While the filing does not quantify pemvidutide’s market potential or compare efficacy to existing therapies, the positive Phase 2 results indicate potential as an additional treatment option pending successful development and approval.
The AUD therapeutic area has seen limited innovation in recent decades, creating opportunities for differentiated treatments. Pemvidutide’s dual glucagon/GLP-1 mechanism offers a novel approach that could fulfill unmet needs and appeal to patients and providers seeking alternatives to current pharmacotherapies.
Investor Outlook and Upcoming Milestones
The RECLAIM Phase 2 success marks a key clinical milestone for Altimmune and its pemvidutide program. Investors will monitor progress toward the planned FDA End-of-Phase 2 meeting and subsequent regulatory guidance. The meeting’s timing and outcomes will provide clarity on the regulatory path and development priorities. Immediate share price impact was not evident at the time of disclosure.
Important upcoming developments include the FDA meeting results, Phase 3 trial design decisions, patient enrollment timelines, and additional clinical or safety data from RECLAIM. Updates on resource allocation, partnerships, or financing related to pemvidutide development may also follow. Investors should recognize that positive Phase 2 results do not guarantee success in pivotal trials or regulatory approval, with inherent scientific, regulatory, and commercial risks ahead.
Company Profile and Disclosure Details
Altimmune, Inc., incorporated in Delaware, is headquartered in Gaithersburg, Maryland. Its common stock trades on the NASDAQ Global Market under the symbol ALT. The July 28, 2026 filing was signed by Gregory Weaver, Chief Financial Officer, and represents current disclosures under applicable securities regulations. No changes to corporate contact information or former addresses were noted.
This announcement follows Regulation FD Disclosure Item 7.01, ensuring simultaneous release of material clinical trial information to all market participants, promoting equal access to important data regarding Altimmune’s clinical development programs.
